Oliver Luxxe Assets LLC Has $5.47 Million Position in AstraZeneca PLC $AZN

Key Points

• Oliver Luxxe Assets LLC increased its stake in AstraZeneca PLC by 6.0% in the second quarter, now holding 78,301 shares valued at $5,472,000.
• AstraZeneca reported earnings of $1.09 per share for the last quarter, meeting analysts' expectations, with a revenue of $14.46 billion, exceeding estimates by $380 million.
• The company recently declared a semi-annual dividend of $0.505, which resulted in a yield of 200.0%, and has a payout ratio of 37.97%.

Oliver Luxxe Assets LLC increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 6.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 78,301 shares of the company's stock after acquiring an additional 4,449 shares during the quarter. Oliver Luxxe Assets LLC's holdings in AstraZeneca were worth $5,472,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Confluence Investment Management LLC bought a new position in AstraZeneca during the first quarter worth about $27,000. Larson Financial Group LLC grew its stake in AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock worth $28,000 after buying an additional 289 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in AstraZeneca during the first quarter worth about $29,000. Costello Asset Management INC acquired a new stake in AstraZeneca during the first quarter worth about $29,000. Finally, Highline Wealth Partners LLC boosted its stake in shares of AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after purchasing an additional 340 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $86.00.

AstraZeneca Trading Up 1.6%

AstraZeneca stock traded up $1.22 during mid-day trading on Monday, hitting $77.50. 4,868,356 shares of the stock were exchanged, compared to its average volume of 3,518,580. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $82.41. The firm's fifty day simple moving average is $76.73 and its two-hundred day simple moving average is $72.94. The stock has a market capitalization of $240.36 billion, a price-to-earnings ratio of 29.14, a PEG ratio of 1.40 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.24 EPS. Analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were paid a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's payout ratio is currently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.